Is Technetium-99m Sestamibi Imaging Able to Predict Pathologic Nonresponse to Neoadjuvant Chemotherapy in Breast Cancer? A Meta-analysis Evaluating Current Use and Shortcomings
- 1 February 2018
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 18 (1) , 9-18
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The Use of Molecular Breast Imaging to Assess Response in Women Undergoing Neoadjuvant Therapy for Breast CancerClinical Nuclear Medicine, 2012
- Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast CancerAnnals of Surgical Oncology, 2011
- Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapyBMC Cancer, 2011
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysisBreast Cancer Research and Treatment, 2011
- Potential value of color-coded dynamic breast-specific gamma-imaging; comparing 99mTc-(V)-DMSA, 99mTc-MIBI, and 99mTc-HDP in a mouse mammary tumor modelApplied Radiation and Isotopes, 2010
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- Integrin scintimammography using a dedicated breast imaging, solid‐state γ‐camera and 99mTc‐labelled NC100692Clinical Physiology and Functional Imaging, 2008
- Monitoring the response of large (>3???cm) and locally advanced (T3???4, N0???2) breast cancer to neoadjuvant chemotherapy using 99mTc-Sestamibi uptakeNuclear Medicine Communications, 2005
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002